Key clinical point: Zilucoplan, a self-administered complement C5 inhibitor, improved measures of muscle weakness and daily function in patients with generalized myasthenia gravis.

Major finding: The mean change in Quantitative Myasthenia Gravis score was –6.0 points for zilucoplan 0.3 mg/kg and –3.2 for placebo (P = .05).

Study details: A randomized, placebo-controlled, phase 2 study including 44 adult patients with acetylcholine receptor autoantibody–positive generalized myasthenia gravis.

Disclosures: Ra Pharmaceuticals funded the study. The lead author reported disclosures related to Ra Pharmaceuticals, Alexion Pharmaceuticals, argenx, Viela Bio, and others.